News | May 28, 2007

MR Focused Ultrasound Relieves Fibroid Symptoms in Women

May 29, 2007 – A noninvasive ultrasound procedure effectively shrinks uterine fibroids and significantly relieves fibroid-related symptoms in women, according to the results of a multicenter clinical trial reported in the June issue of the journal Radiology. Magnetic resonance-guided, focused ultrasound surgery (MRgFUS) allows radiologists to precisely target fibroids without harming healthy surrounding tissue.

“This treatment immediately stops blood flow in the treated fibroid tissue, which results in a significant, sustained decrease in symptoms for up to 12 months,” said the study’s lead author, Fiona M. Fennessy, M.D., Ph.D., assistant professor of radiology at Harvard Medical School and staff radiologist at Brigham and Women’s Hospital in Boston.

Uterine fibroids are benign growths of the muscle inside the uterus. According to the National Institutes of Health, at least 25 percent of women in the United States age 25 to 50 suffer from symptomatic uterine fibroids. Fibroid symptoms can include excessive menstrual bleeding, enlarged uterine size, frequent urination, pelvic pressure or pain and infertility. According to the National Women’s Health Information Center, fibroids are the primary reason for surgical removal of the uterus, accounting for approximately one-third of hysterectomies performed annually in the U.S.

MRgFUS represents a noninvasive, outpatient alternative to hysterectomy. “This treatment is ideal for older women who have completed their families and have a single or limited number of fibroids,” said co-author Clare M. Tempany, M.D., professor of radiology at Harvard Medical School and director of Clinical Focused Ultrasound at Brigham and Women’s Hospital.

The researchers studied 160 women with symptomatic fibroids. The women received pre-treatment MR imaging to identify and define the target fibroids. Radiologists then used MRgFUS to locate and treat the targeted fibroids while monitoring temperature changes in tissue.
Ninety-six patients were treated under the original study protocol (A), and 64 patients were treated under an optimized protocol (B). Protocol A allowed a maximum treatment time of 120 minutes and a maximum fibroid treatment volume of 100ccs (roughly six centimeters (cm) in diameter), or up to 33 percent of total fibroid volume. Protocol B allowed a maximum treatment time of 180 minutes and maximum fibroid treatment volume of 150ccs (about seven cm in diameter), or up to 33 percent of total volume in subserosal fibroids (those on the outer wall of the uterus) and 50 percent of volume in non-subserosal fibroids.

“Through this study, we’ve learned that MRgFUS can be optimized with newer protocols to have even better results than previously thought possible,” Dr. Tempany said.

The findings showed significant symptom relief at three months and sustained relief at one year. Women treated with the optimized protocol reported greater symptom relief and quality of life improvement than those treated with the original protocol. No serious adverse effects were reported.

“We have shown that treating fibroids with an optimized, less restrictive protocol allows for treatment of a greater fibroid volume, which results in even greater symptomatic relief at clinical follow-up,” Dr. Fennessy said.

Source: RSNA Media Relations
Linda Brooks
1-630-590-7738
[email protected]

Related Content

Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Ultrasound Imaging | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cardiac Imaging | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Siemens Healthineers Announces First Installation of Acuson Sequoia Ultrasound
News | Ultrasound Imaging | September 20, 2018
September 20, 2018 — Siemens Healthineers announced the first global installation of its newest...
LVivo EF Cardiac Tool Now Available for GE Vscan Extend Handheld Mobile Ultrasound
Technology | Cardiovascular Ultrasound | September 19, 2018
DiA Imaging Analysis Ltd. (DiA), a provider of artificial intelligence (AI)-powered ultrasound analysis tools,...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Acuson Sequoia
News | Ultrasound Imaging | September 12, 2018
Siemens Healthineers announced the first global installation of its newest ultrasound system, the...
Mount Sinai Serves as Official Medical Services Provider for 2018 U.S. Open
News | Orthopedic Imaging | September 06, 2018
For the sixth consecutive year, Mount Sinai will serve as the official medical services provider for the 2018 U.S. Open...
Konica Minolta Provides Sonimage HS1 Ultrasound for AAPM&R Hands-on Learning Course
News | Ultrasound Imaging | September 05, 2018
Konica Minolta Healthcare Americas recently provided ultrasound systems for The American Academy for Physical Medicine...
Philips Launches Epiq CVx and CVxi Cardiovascular Ultrasound Systems
Technology | Cardiovascular Ultrasound | August 22, 2018
Philips recently announced the introduction of the Epiq CVx cardiovascular ultrasound system. Built on the Epiq...
Fujifilm SonoSite Unveils Full Suite of iViz Point-of-Care Transducers

The L25v ultrasound transducer for the Fujifilm Sonosite iViz is available for superficial applications such as ophthalmic, arterial, venous, lung and nerve. Image courtesy of Fujifilm Sonosite.

Technology | Ultrasound Imaging | August 15, 2018
Fujifilm SonoSite Inc. announced the launch of two new transducers for the SonoSite iViz point-of-care ultrasound, now...